Osimertinib vs standard of care EGFR-TKI as first-line therapy in patients with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes-MedSci.cn

Osimertinib vs standard of care EGFR-TKI as first-line therapy in patients with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes

Grohe, C; Bischoff, H; Bohnet, S; zum Buschenfelde, CM; Reinmuth, N; Ruckert, A

ONCOLOGY RESEARCH AND TREATMENT, 2018; 41 (): 269

科室
- - 订阅+
  - 更多科室
工具
服务